Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-Iodotyrosine** is a halogenated derivative of the amino acid tyrosine, specifically iodinated at the meta (3-) position of the benzene ring. It serves as an intermediate in thyroid hormone biosynthesis, formed by iodination of tyrosine within the thyroid gland. In this pathway, one unit of 3-iodotyrosine can combine with diiodotyrosine to form triiodothyronine (T₃), and two units can combine to form 3,3'-diiodothyronine[2][10]. Beyond its physiological role in thyroid hormone synthesis, it is also a reversible inhibitor of tyrosine hydroxylase—the rate-limiting enzyme in catecholamine (dopamine) biosynthesis—making it useful for research into dopamine pathways and neurodegenerative diseases[2][10]. It is not approved as a pharmaceutical drug but is widely used experimentally for biochemical assays and metabolic studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-iodotyrosine.